Elsevier logo

Publisher: Elsevier

Related content
Volume 35, Number 3, September 2001

< previous issue | all issues | next issue >

The Bridge - September 2001
pp. 315-315(1)
Author: Reichen J.

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
pp. 316-323(8)
Authors: Menon K.V.N.; Angulo P.; Weston S.; Dickson E.R.; Lindor K.D.

Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?
pp. 324-328(5)
Authors: Corpechot C.; Benlian P.; Barbu V.; Chazouilleres O.; Poupon R.E.; Poupon R.

Early shifts of adrenal steroid synthesis before and after relief of short-term cholestasis
pp. 329-337(9)
Authors: Zietz B.; Wengler I.; Messmann H.; Lock G.; Scholmerich J.; Straub R.H.

The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome
pp. 338-343(6)
Authors: Tang T.J.; Batts K.P.; de Groen P.C.; van Hoek B.; Haagsma E.B.; Hop W.C.J.; Janssen H.L.A.

Venesection therapy of insulin resistance-associated hepatic iron overload
pp. 344-349(6)
Authors: Guillygomarc'h A.; Mendler M.H.; Moirand R.; Laine F.; Quentin V.; David V.; Brissot P.; Deugnier Y.

Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis
pp. 367-375(9)
Authors: Grenard P.; Bresson-Hadni S.; El Alaoui S.; Chevallier M.; Vuitton D.A.; Ricard-Blum S.

Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis
pp. 376-385(10)
Authors: Paizis G.; Gilbert R.E.; Cooper M.E.; Murthi P.; Schembri J.M.; Wu L.L.; Rumble J.R.; Kelly D.J.; Tikellis C.; Cox A.; Smallwood R.A.; Angus P.W.

Modulation of collagen XVIII/endostatin expression in lobular and biliary rat liver fibrogenesis
pp. 386-391(6)
Authors: Jia J.-D.; Bauer M.; Sedlaczek N.; Herbst H.; Ruehl M.; Hahn E.G.; Riecken E.O.; Schuppan D.

Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1
pp. 392-398(7)
Authors: Jia J.-D.; Bauer M.; Cho J.J.; Ruehl M.; Milani S.; Boigk G.; Riecken E.O.; Schuppan D.

Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment
pp. 399-405(7)
Authors: Gervais A.; Martinot M.; Boyer N.; Auperin A.; Le Breton V.; Degott C.; Valla D.; Marcellin P.

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial
pp. 406-411(6)
Authors: Barbaro G.; Zechini F.; Pellicelli A.M.; Francavilla R.; Scotto G.; Bacca D.; Bruno M.; Babudieri S.; Annese M.; Matarazzo F.; Di Stefano G.; Barbarini G.; for the Lamivudine Italian Study Group Investigators

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
pp. 421-430(10)
Authors: Bruix J.; Sherman M.; Llovet J.M.; Beaugrand M.; Lencioni R.; Burroughs A.K.; Christensen E.; Pagliaro L.; Colombo M.; Rodes J.

Abnormal hepatic enhancement on CT in congestive heart failure
pp. 431-431(1)
Authors: de las Heras D.; Pages M.

Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy?
pp. 432-433(2)
Authors: Giannini E.; Ceppa P.; Testa R.

Reply
pp. 433-433(1)
Authors: Clouston A.D.; Hickman I.J.; Macdonald G.A.; Jonsson J.R.; Powell E.E.

< previous issue | all issues | next issue >

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page